Tofacitinib in cardiovascular outcomes: friend or foe?

MLA

Zhuoli Zhang, and Wenhui Xie. “Tofacitinib in Cardiovascular Outcomes: Friend or Foe?” Rheumatology, vol. 59, Mar. 2020, pp. 1797–98. EBSCOhost, https://doi.org/10.1093/rheumatology/keaa090.

APA

Zhuoli Zhang, & Wenhui Xie. (2020). Tofacitinib in cardiovascular outcomes: friend or foe? Rheumatology, 59, 1797–1798. https://doi.org/10.1093/rheumatology/keaa090

Chicago

Zhuoli Zhang, and Wenhui Xie. 2020. “Tofacitinib in Cardiovascular Outcomes: Friend or Foe?” Rheumatology 59 (March): 1797–98. doi:10.1093/rheumatology/keaa090.